EUCTR2010-022810-26-DE进行中（未招募）不适用
MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA - PERCAT
niversity Witten/Herdecke0 个研究点目标入组 40 人开始时间: 2010年11月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed and dated informed consent
- •Age ? 18 years
- •Patient is suffering from EPCAM-positive peritoneal carcinoma-tosis of colorectal or gastric adenocarcinoma, which was con-firmed by histological analysis.
- •ECOG status 1 or 2 (Karnofsky index ? 70)
- •Patient is not eligible for surgical cytoreduction followed by hy-perthermic intraperitoneal chemotherapy (see Attachments for selection criteria).
- •Patient is eligible for FOLFOX or FOLFIRI treatment in case of colorectal cancer; patient is eligible for FLO or FLOT treatment in case of gastric cancer (i.e. no intolerance or hypersensitivity, no tumor progression during treatment)
- •Body mass index > 17
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Symptomatic ascites (estimated accumulation of more than 1500 ml by sonography and computer tomography and punc-ture of more than 1500 ml)
- •Ileus or abdominal obstruction with the need of surgical inter-vention at inclusion or parenteral feeding (> 30% of daily calo-rie intake)
- •Previous use of non-humanized monoclonal mouse or rat anti-bodies
- •Known or suspected hypersensitivity or allergy to Catu-maxomab or to similar antibodies
- •Presence of any acute or chronic systemic infection
- •Pre-existing heart failure: NYHA class > II
- •Pregnancy or breast feeding
- •Other concurrent uncontrolled medical conditions
- •Previous Catumaxomab therapy
- •Medical or psychiatric conditions that compromise the patient’s ability to give informed consent
- •Inadequate renal function (Creatinine >1,5 x ULN)
- •(PTT) Partial thromboplastine time > x ULN
- •Inadequate hepatic function (AST or ALT > 2.5 x ULN or Bilirubin > 2 x ULN)
- •Inadequate bone marrow function with platelets < 100 000 cells/mm3 or absolute neutrophil count (ANC) < 1500 cells/mm3 or a proportion of < 15% of lymphocytes in differential blood count
- •Pregnant or nursing women, or women of childbearing potential who are not using an effective contraceptive method during the study and at least three months after the last infusion (i.e., oral or injectable contraceptives, intrauterine devices, double-barrier method, contraceptive patch, male partner sterilization or condoms)
- •Any further condition which, according to the investigator, re-sults in an undue risk to the patient during participation in the present study
- •Parallel participation in another clinical trial
- •Previous participation in the present study
- •Treatment with another investigational product during this study or during the last 30 days prior to study start (day 0)
研究者
相似试验
进行中（未招募）
1 期
Study to investigate the combination of Lanreotide Autogel 120mg and Temozolomid in patients with WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMOURSmetastatic functioning and non-functioning entero-pancreatic tumoursEUCTR2013-001697-17-ATIpsen Pharma GmbH65
进行中（未招募）
1 期
Study to investigate the combination of Lanreotide Autogel 120mg and Temozolomid in patients with WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMOURSmetastatic functioning and non-functioning entero-pancreatic tumoursEUCTR2013-001697-17-DEIpsen Pharma GmbH65
进行中（未招募）
1 期
Study of U3-1402 in subjects with colorectal cancerAdvanced or metastatic colorectal cancer (CRC) which is resistant, refractory, or intolerant to at least 2 prior lines of therapy, that must include all of the following agents: fluoropyrimidine, irinotecan, platinum agent, an anti-epidermal growth factor receptor (EGFR) agent (if clinically indicated) and, unless contraindicated, an anti- vascular endothelial growth factor (VEGF) agent.MedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2019-004418-32-ITDAIICHI SANKYO INC.80
已完成
2 期
A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3- 1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC)Metastatic Colorectal CancerJPRN-jRCT2031200139Inoguchi Akihiro80
进行中（未招募）
1 期
Study of U3-1402 in subjects with colorectal cancerEUCTR2019-004418-32-PLDAIICHI SANKYO, INC80